Ang mga hugaw sa amino acid nga gigamit alang sa synthesize protina
Detalye sa Produkto
| NO | Mga produkto | Cas no | Panguna nga kalidad nga Indicator | |||
| Kalig-on | Max. pagkadungog | Kabuangan nga Pagbag-o sa Solvent | Umog | |||
| 1 | Fmoc-β-ala-ala-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 2 | Fmoc-d-ala-d-ala-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 3 | Fmoc-β-ala-d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 4 | FMOC-ARG (PBF) -arg (PBF) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 5 | Fmoc-β-ala-arg (pbf) -o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 6 | FMOC-D-ARG (PBF) -D-ARG (PBF) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 7 | Fmoc-β-D-D-ARG (PBF) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 8 | FMOC-HOMOARG (PBF) -HOMOARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 9 | Fmoc-β-ala-homoarg (PBF) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 10 | FMOC-ASN (TRT) -ASN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 11 | Fmoc-β-AA-ALN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 12 | FMOC-ASP (OTBU) -Apasp (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 13 | Fmoc-β-ALA-ALP (OTOBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 14 | FMOC-CYS (TRT) -CYS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 15 | Fmoc-β-ala-cys (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 16 | FMOC-CYS (ACM) -CYS (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 17 | Fmoc-β-ala-cys (acm) -o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 18 | FMOC-GLN (TRT) -Gln (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 19 | Fmoc-β-ala-gln (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 20 | FMOC-GLU (OTOBU) -GUP (OTOBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 21 | Fmoc-β-glu-glu (otbu) -oh.h2o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 22 | Fmoc-β-gly-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 23 | Fmoc-ang iyang (TRT) -HIS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 24 | Fmoc-β-ala-iyang (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 25 | Fmoc-ile-ile-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 26 | Fmoc-β-ala-ile-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 27 | Fmoc-leu-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 28 | Fmoc-β-ala-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 29 | FMOC-D-leu-D-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 30 | Fmoc-β-ala-d-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 31 | FMOC-lys (BOC) -LYS (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 32 | Fmoc-β-ala-lys (BOC) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 33 | Fmoc-lys (alloc) -lys (alloc) -o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 34 | FMOC-β-ala-lys (alloc) -o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 35 | FMOC-met-met-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 36 | FMOC-β-ala-met-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 37 | FMOC-ORN (BOC) -NOL (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 38 | Fmoc-β-ala-orn (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 39 | Fmoc-phe-phe-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 40 | Fmoc-β-ala-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 41 | Fmoc-d-phe-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 42 | Fmoc-β-d-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 43 | Fmoc-pro-pro-pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 44 | Fmoc-β-ala-pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 45 | FMOC-SER (TBU) -SER (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 46 | Fmoc-β-ala-ser (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 47 | FMOC-SER (TRT) -SER (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 48 | Fmoc-β-ala-ser (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 49 | Fmoc-thr (tbu) -thr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 50 | Fmoc-β-ALA-THRO (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 51 | FMOC-TRP (BOC) -TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 52 | Fmoc-β-ala-trp (BOC) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 54 | Fmoc-β-D-TRP (BOC) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 55 | Fmoc-Tyr (Tbu) -Tyr (Tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 56 | Fmoc-β-ala-tyr (Tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 57 | Fmoc-D-Tyr (et) -d-Tyr (et) -o -o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 58 | Fmoc-β-d-d-tyr (et) -o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 59 | Fmoc-tyr (me) -Tyr (ako) -o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 60 | Fmoc-β-ala-tyr (ako) -o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 61 | Fmoc-val-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 62 | Fmoc-β-ala-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 63 | FmoC-D-CIT-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 64 | Fmoc-β-ala-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 65 | Fmoc-β-ala-dab-oh-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 66 | FMOC- (3- (2-naphthyl) -D-ala) 2-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 67 | Fmoc-β-ala-3- (2-naphthyl) -d-ala- | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 68 | FMOC- (3- (3-Pyridinyl) -D-ala) 2-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 69 | Fmoc-β-ala-3- (3-pyridinyl) -d-ala- | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 70 | Fmoc- (4-chloro-d-phe) 2-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 71 | Fmoc-β-ala-4-chloro-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 72 | FMOC- (D-4APH (TBUCBM)) 2-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 73 | Fmoc-β-D-4Aaph (tbuucbm) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 74 | Fmoc-aph (l-hor) -aph (L-hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 75 | Fmoc-β-ala-aph (L-hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 76 | Fmoc-Lys (IPR, BOC) -LYS (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 77 | Fmoc-β-ala-lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 78 | Fmoc-β-ala-Aeea-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 79 | Fmoc-AIB-AIB-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 80 | Fmoc-β-ala-aib-a | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 81 | Fmoc-arg-oh | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 82 | H-ARG (PBF) -Oh | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 83 | Fmoc-d-arg-oh | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 84 | HD-ARG (PBF) -Oh | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 85 | Fmoc-homoarg-ohcl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 86 | H-Homoarg (PBF) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 87 | Fmoc-d-homoarg-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 88 | HD-Homoarg (PBF) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 89 | Fmoc-asn-oh | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 90 | H-Asn (TRT) -OH | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 91 | Fmoc-asp-oh | 119062-05-4-4-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 92 | H-ASP (OTOBU) -OH | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 93 | Fmoc-cys-oh | 135248-89-49-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 94 | H-cys (TRT) -OH | 2799/7/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 95 | H-cys (acm) -oh.hcl | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 96 | Fmoc-gln-oh | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 97 | H-GLN (TRT) -OH | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 98 | Fmoc-gligo-oh | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 99 | H-glu (otbu) -oh.h2o | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 100 | Fmoc-shmoc-shmoc-oh | 1166111-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 101 | H-iyang (TRT) -OH | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 102 | BOC-IYA-OH | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 103 | Fmoc-lys-oh | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 104 | H-lys (BOC) -OH | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 105 | H-lys (alloc) -oh | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 106 | Fmoc-orn-ohcl | 201046-57-3-3-3-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 107 | H-ORN (BOC) -OH | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 108 | Fmoc-Ser-oh | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 109 | H-ser (tbu) -oh | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 110 | H-ser (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 112 | H-thr (tbu) -oh | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 113 | Fmoc-trp-oh | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 114 | H-TRP (BOC) -OH | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 115 | FMOC-D-TRP-OH | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 117 | Fmoc-tyr-oh | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 118 | H-tyr (tbu) -oh | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 119 | Fmoc-d-Tyr-oh | 1128883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 120 | HD-Tyr (et) -o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 121 | H-Tyr (ako) -oh.hcl | 67423-34-34 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 122 | FMOC-D-4APH (CBM) -OH | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 123 | HD-4APH (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 124 | Fmoc-lys (IPR) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 125 | H-lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
Labot sa
Bayad
Ang Gentorex naghatag daghang kalidad nga mga produkto, kung adunay bisan unsang kalidad sa produkto nga gipadako sa kliyente sa sulod sa gikinahanglan nga oras sa oras nga adunay igong pag-analisar ug pagtimbangtimbang aron ma-trigger ang mga bayad.
Produksyon
Ang mga kapasidad sa mga produkto sa Pharmaceutical nakaabot sa grado nga grado, ang mga kapasidad sa mga produktong kemikal nga nakaabot sa 100tons + Grado, ang mga kapabilidad maayo nga nasangkapan sa mga kliyente sa tibuuk kalibutan.
Panukiduki ug pag-uswag
Kada tuig, adunay plano nga gitakda sa R & D team aron mapalambo ang lainlaing mga produkto, kung ang mga target nga gitakda, ang matag miyembro sa koponan kinahanglan nga magpadayon sa palisiya sa KPI ug sa palisiya sa insentibo.
